Skip to main content

Navigation group

Type at least 3 characters
14,374 articles

Articles

Original Research

Accepted on 23 May 2024

Safety and Efficacy of Nintedanib as Second-Line Therapy for Patients with Differentiated or Medullary Thyroid Cancer Progressing After First Line Therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209

in Thyroid Endocrinology

  • Sophie Leboulleux
  • Ellen Kapiteijn
  • Saskia Litière
  • Patrick Schöffski
  • Yann Godbert
  • Patrice Rodien
  • Barbara Maria Jarzab
  • Domenico Salvatore
  • Sylvie Zanetta
  • Jaume Capdevila
Frontiers in Endocrinology
doi 10.3389/fendo.2024.1403687